SRTS stock: buy or sell?
February 27th, 2020
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide.
Should I buy SRTS stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Sensus Healthcare stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Sensus Healthcare stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for SRTS stock for the last 30 days.
SRTS stock analysis
After boosting an outstanding 7.39% yesterday, Sensus Healthcare closed today at $3.70 and collapsed a spooky -8.87%.
After boosting an outstanding 7.39% yesterday, Sensus Healthcare closed today at $3.70 and collapsed a spooky -8.87%. Since last Feb/20 when SRTS stock price broke down the SMA100d line, it slid $-0.75 per share (-16.85%).
Sensus Healthcare shares collapsed -14.55% this week, ending at $3.70. Early February SRTS climbed an amazing 12.74% in just one week. With this, it's been 3 sliding weeks in a row, loosing $-1.01 (-24.57%).
Sensus Healthcare is in a glaring downtrend, marking successive declining peaks and bottoms. Now is trading in between the - range. If the support holds the price, this might mark a double bottom shape and create a flat-base to reverse this downtrend. Far behind is the all-time high Sensus Healthcare hit by mid March 2019 and since then the price is -59.91% below that top. Since price and 40-weeks moving average lines crossed down late March 2019, SRTS fell $-3.65 per share (-49.66%). Stocks under the 200 days moving average line are usually not recommended for average traders.
SRTS stock price history
SRTS stock went public on July 28th, 2016 with a price of $6.501. Since then, SRTS stock lost a -43.10%, with a yearly average of -14.40%.
1: Adjusted price after possible price splits or reverse-splits.
SRTS stock historical price chart
SRTS stock reached all-time highs on March with a price of $9.23.
SRTS stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price target for Sensus Healthcare stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report , Sensus Healthcare . As soon as we get its actual EPS from the earnings report, we will update this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a dazzling gain of 28.36% to $26.43 M USD. When comparing 2018 vs 2017, in the same way, profit margin (that is, the net income divided by revenues) rocketed a 10.37% to -7.65%.
|2013||$10 M||-||$0.11 M1.0%||-|
|2014||$5.81 M||-44.56%||$-3.70 M-63.7%||-3,537.31%|
|2015||$10 M||76.81%||$-0.24 M-2.3%||-93.59%|
|2016||$15 M||44.17%||$-0.35 M-2.3%||46.02%|
|2017||$21 M||39.00%||$-3.71 M-18.0%||971.01%|
|2018||$26 M||28.36%||$-2.02 M-7.7%||-45.49%|
Quarterly financial resultsSensus Healthcare reported $8.08 million in revenues for 2018-Q4, a 27.58% up compared to previous quarter. Reported quarter income marked $0.10 M with a profit margin of 1.26%. Profit margin rose a 8.49% compared to previous quarter when profit margin was -7.23%. When comparing revenues to same quarter last year, Sensus Healthcare sales marked a super good gain and climbed a 24.91%. Looking back to recent quarterly results, Sensus Healthcare posted 3 positive quarters in a row.
|2017-Q1||$4 M||-||$-1.57 M-36.1%||-|
|2017-Q2||$5 M||14.25%||$-0.76 M-15.4%||-51.33%|
|2017-Q3||$5 M||-3.51%||$-0.97 M-20.1%||26.38%|
|2017-Q4||$6 M||34.91%||$-0.41 M-6.3%||-57.69%|
|2018-Q1||$6 M||-7.95%||$-1.13 M-18.9%||175.56%|
|2018-Q2||$6 M||1.70%||$-0.54 M-8.9%||-51.98%|
|2018-Q3||$6 M||4.58%||$-0.46 M-7.2%||-15.27%|
|2018-Q4||$8 M||27.58%||$0.10 M1.3%||-122.25%|
Sensus Healthcare ownershipWhen you are planning to invest in a company, it's always worth to check its ownership structure.
Sensus Healthcare shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
The following table compares ownership indicators for other stocks related to Sensus Healthcare:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Thursday, February 27th, 2020|
|Day range||$3.57 - $4.14|
|Average true range||$0.38|
|50d mov avg||$4.04|
|100d mov avg||$4.34|
|200d mov avg||$5.01|
Sensus Healthcare performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected as the bechmarking frame for Sensus Healthcare stock.